Interestingly, their results also showed that serum prostate-specific antigen (PSA) levels and PSA density (serum PSA level divided by tumor volume) values in the EGCG-treated mice were significantly lower than those in control mice [36]. The gene discussed is KLK3; the disease is neoplasm.